Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158203 | 0.98 | GAA (0.35) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL5158192 | 0.72 | PTGS2 (0.36) | KMT2AMEN1KDM4EALDH1A1CYP2D6 | |
| SCHEMBL5160367 | 0.68 | CHRNA7 (0.33) | KMT2AMEN1KDM4EALDH1A1TSHR | |
| SCHEMBL5158247 | 0.68 | SIGMAR1 (0.36) | TSHRCYP2D6SLC6A4SLC6A3 | |
| SCHEMBL28721926 | 0.67 | KMT2A (0.46) | KMT2AMEN1KDM4EALDH1A1GAA | |
| SCHEMBL5159848 | 0.67 | MEN1 (0.39) | KMT2AMEN1TSHRSLC6A4SLC6A3 | |
| SCHEMBL674996 | 0.67 | CHRNA7 (0.59) | KMT2AMEN1KDM4EALDH1A1LMNA | |
| SCHEMBL14772603 | 0.66 | ROCK2 (0.33) | KMT2AMEN1GAAL3MBTL1IDO1 | |
| SCHEMBL5160256 | 0.66 | SIGMAR1 (0.38) | HTR2ASLC6A4OPRM1SLC6A3 | |
| SCHEMBL5158439 | 0.65 | CHRNB4 (0.41) | KMT2AMEN1ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | claimed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | claimed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | claimed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | claimed |
| EP-1406857-B1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARYL-BUT-2-ENYLAMINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-7064236-B2 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2006-06-20 | — | — | US | disclosed |
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | GRUNENTHAL GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| EP-1406857-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003004452-A1 | SUBSTITUTED 1-ARYL-BUT-3-ENYLAMINE AND 1-ARY-BUT-2-ENYLAMINE COMPOUNDS | Grünenthal GmbH (DE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171615-A1 | Substituted 1-aryl-but-3-enylamine and 1-aryl-but-2-enylamine compounds | ADRB3, BRD4, NAT1 | KMT2A 2909/4885MEN1 1165/4885KDM4E 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.